Using Chinese Herbal Medicine among Cancer Survivors: Data from a Community Hospital in China.
Ying Wang,Hui Wang,Yu Wan,Xiaoyan Wang,Yiling Jiang,Han Zhang,Yi‐Fang Zhao,Feng Chai,Hongming Fang,Weidong Lu
DOI: https://doi.org/10.1200/jco.2016.34.3_suppl.e284
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e284 Background: Chinese Herbal Medicine (CHM) is a major component of Traditional Chinese Medicine (TCM) that is widely used in Asian countries. In China, an estimated 397.7 million outpatients and 14.8 million inpatients were cared by TCM physicians and hospitals annually. TCM usage is even higher among pts with cancer. It is reported that 80% of pts with cancer use CHM and 90% of oncologists have prescribed CHM in practice. We reviewed CHM practice among cancer survivors in our hospital, a community general hospital with 800 beds located in the east coast of China. METHODS A retrospective review was conducted by searching outpatient medical records from June 2012 to August 2015. Pts were eligible if pts have pathologically proven cancer and who have completed main anticancer therapies and used CHM prescribed in the outpatient clinic. Descriptive statistical and survival analysis were performed using SPSS. RESULTS A total of 300 pts were identified, with a median age of 62 years (31-90), 53% were male, with 36 types of cancers. The most common cancers were lung (32%), breast (15%), colorectal (12%), stomach (9%) and liver (6%). 48% pts had stage IV disease. 47% pts used CHM for health maintenance and 53% pts used CHM for anticancer intent. 57% pts used CHM exclusively and 43% used CHM in addition to standard therapies. The median number of outpatient visits was 17 (1-158) with an average of 19 prescribed herbs per person at each visit. During the period, 36% pts passed away with a median overall survival of 24. 9 months (2-108 months). CONCLUSIONS Using CHM for health maintenance or anticancer intent is common among Chinese cancer survivors. A majority of cancer survivors used CHM exclusively without other interventions. Future research should focus on whether using CHM has any survival benefits in cancer survivors.